Home›Trial›NCT04181827
🔬NCT04181827Phase 3ACTIVE NOT RECRUITING

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Study Summary

The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).

Conditions
Multiple Myeloma
Interventions / Drugs
Cilta-celPomalidomideBortezomibDexamethasoneDaratumumab
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment419 participants
Primary Completion—
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.549917+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.